Lv1
50 积分 2021-07-24 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
3天前
已完结
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
3天前
已完结
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
1个月前
已完结
Risk factors of cytokine release syndrome: stress, catecholamines, and beyond
1个月前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
2个月前
已完结
Targeting KRAS in cancer
3个月前
已完结
Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell–Engaging Cancer Therapies
3个月前
已完结
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
3个月前
已完结
Cytokine Release Syndrome Biology and Management
3个月前
已完结
Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy
4个月前
已完结
皖公网安备34019202002308
